Understand the source comparison
Low Testosterone Peptides 2026 Update: Compound Comparison
Kisspeptin-54 GnRH neuron activation → LH/FSH release 4–6.4 nmol/kg SC 90–120 min Maintained (no negative feedback suppression) Phase 2 trials (Imperial College, UK) MK-677 (Ibutamoren) Ghrelin receptor agonist → GH/IGF-1 elevation 12.5–25mg oral daily 24 hour
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Kisspeptin-54
- GnRH neuron activation → LH/FSH release
- 4–6.4 nmol/kg SC
- 90–120 min
- Maintained (no negative feedback suppression)
- Phase 2 trials (Imperial College, UK)
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist → GH/IGF-1 elevation
- 12.5–25mg oral daily
- 24 hours
- Preserved (indirect via IGF-1 modulation)
- Phase 2 completed; not FDA-approved
- Thymalin
- Thymic bioregulator → immune-endocrine crosstalk
- 5–10mg IM over 10 days
- Unknown
- Likely preserved (no direct HPG suppression)
- Eastern European clinical studies
- Gonadorelin
- Direct GnRH analog → LH/FSH secretion
- 100mcg SC 2–3x daily
- 2–4 minutes
- Maintained (restores physiological pulsatility)
- FDA-approved diagnostic use
- CJC-1295 / Ipamorelin
- GHRH analog + GH secretagogue → pulsatile GH release
- 100–300mcg SC 1–2x daily
- CJC: 6–8 days; Ipa: 2 hours
- Likely preserved (indirect pathway)
- Preclinical and early clinical research